Real-World Impact
Where did the largest Real-world flu effectiveness study to date take place?
Kaiser Permanente
Flublok is approved for use in individuals ____ years of age or older
9
The most common solicited systemic adverse reactions.
Headache, fatigue, and muscle pain.
A PIVOTAL TRIAL IN PATIENTS AGED 18-49 FOUND _______ FEWER FLU CASES WITH FLUBLOK due to any culture-confirmed CDC defined ILI strain, regardless of match to the vaccine
44.6% (95% CI: 18.8, 62.6)
Recombinant Technology leads to a _____ immune response
broader
In the KP study, Flublok was associated with ____% fewer flue cases compared to SD vaccines in adults age 50-64.
15.3%
Flublok is among the flu vaccines preferentially recommended by ____ for those age 65+ vs _______ standard dose vaccines
ACIP and unadjuvanted
Systemic symptoms following vaccination were ______ between people receiving Flublok and placebo
similar
FLUBLOK WAS ASSOCIATED WITH PREVENTING __________ FLU DESPITE SIGNIFICANT ANTIGENIC MISMATCH BETWEEN THE VACCINE ANTIGENS AND CIRCULATING VIRUSES.
CULTURE-CONFIRMED
Vaccinating with Flublok may lead to a _____ greater antibody response vs cell and egg-based SD vax.
greater
Beyfortus is FDA approved for all infants entering their first RSV season, including those born:
1.
2.
3.
1. Healthy or with underlying conditions
2. Full term or preterm
3. Before or during the RSV season
Flublok's presentation and dose:__________
10 single-dose 0.5mL PFS
Do not administer Fluzone, Flublok, or Fluzone High-Dose to anyone with a history of a severe allergic reaction (e.g., ________) to any component of the vaccine (including egg protein for Fluzone and Fluzone High-Dose). Fluzone and Fluzone High-Dose should not be administered to anyone who has had a severe allergic reaction after previous dose of any influenza vaccine.
anaphylaxis
In the Dunkle study, Flublok demonstrated ____% better flu protection when compared to Fluarix in adults 50+
30%
Flublok is the ONLY flu vaccine that does not use the _______ in any part of the manufacturing process
influenza virus
Flublok was associated with ____% fewer flu hospitalizations vs SD vaccines in ~ ______ patients age 18+ across multiple flu seasons
31% and ~15K
Flublok ensures identical antigenic match with FDA-selected flu strains. Recombinant technology eliminates the risk of ________ that can occur with cell- or egg-based vaccines.
mutations
If ____________ has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give Flublok should be based on careful consideration of the potential benefits and risks.
Guillain-Barré syndrome
FLUBLOK DEMONSTRATED ______ IMMUNE RESPONSE IN PATIENTS AGED 9-17 COMPARED TO ADULTS AGED 18-491,
NON-INFERIOR
Flublok contains ___x the antigen content of ____ and ____ based standard dose vaccines
3x, cell, egg
In fact, The CDC reported that in the 2019-2020 flu season, a _____ of flu-related deaths and 2 in 5 of all flu-related hospitalizations occurred in adults aged 18-64
THIRD
CROSS-PROTECTION MAY BE A RESULT OF SIMPLER ________ BECAUSE RECOMBINANT DNA TECHNOLOGY ALLOWS FOR BROADER ACCESS TO CONSERVED ANTIGENIC SITES3
GLYCOSYLATION
Syncope (_______) has been reported following vaccination with Fluzone, Flublok and Fluzone High-Dose. Procedures should be in place to avoid injury from fainting.
(fainting)
The secondary endpoint of the Dunkle study showed _______ fewer culture confirmed circulating cases of the flu compared to standard-dose flu vaccine
43%
The ONLY flu vaccine produced with ___________. This ensures identical ________ match with WHO and FDA-selected strains. This technology eliminates the risk of mutations that occur with _____ or _____ based vaccines.
1. recombinant DNA technology.
2. antigenic
3. cell
4. egg